Dermatology — National Leader CAR-T via PKU Network Public · Grade 3A Established 1999 IMC Available

Peking University Shenzhen Hospital
PKU Health Science Centre, Futian District

Shenzhen's foremost destination for dermatology and skin cancer — and a growing precision oncology hub with direct access to Peking University's CAR-T clinical trial network. The International Medical Centre provides private-level intake within a public hospital, making world-class expertise accessible to international patients without private hospital pricing.

1120 Lianhua Road, Futian District, Shenzhen — ~25 min from Shenzhen Bay Port
2,500+
Inpatient beds
Grade 3A
China's highest classification
Top 3
PKU hospital network rank
IMC
International patient centre
About the Hospital

Peking University in Shenzhen — Where Academic Oncology Meets a Growing Tech Hub

Peking University Shenzhen Hospital (北京大学深圳医院) was established in 1999 as a direct branch of China's most prestigious university hospital system. Situated in Futian District — Shenzhen's administrative and financial centre — it holds Grade 3A status and functions as one of the city's primary referral hospitals for both dermatology and cancer care.

The hospital's dermatology department has been designated a national clinical centre of excellence and sees case volumes that few other hospitals in China match. For oncology patients, the connection to Peking University's broader academic network means access to clinical trial pipelines and NGS genomic profiling protocols that feed directly from PKU research programmes in Beijing. The IMC provides a dedicated intake path for international patients, operated separately from the main outpatient flow.

"The PKU network gives Shenzhen patients access to Beijing-level oncology expertise — the clinical trial linkage is especially meaningful for patients exploring CAR-T or experimental protocols."
Why Patients Choose PKU Shenzhen

Three reasons international patients choose Peking University Shenzhen Hospital

National-Level Dermatology & Skin Cancer

The dermatology department holds national clinical centre designation and manages the full spectrum of skin conditions — from autoimmune skin disease to melanoma and cutaneous lymphoma. For patients with complex skin presentations or skin cancer requiring specialist second opinion, this is one of the strongest departments in southern China. International patients can access the department through the IMC with a proxy consultation arranged by China Care in advance of travel.

CAR-T Access via the Peking University Trial Network

As a PKU-affiliated hospital, this Shenzhen campus has access to the Peking University clinical trial pipeline — including CAR-T cell therapy protocols and haematology trials that originate from the Peking University People's Hospital network. For patients who need CAR-T but prefer Shenzhen's proximity to Hong Kong, this hospital provides a viable entry point to PKU-network oncology expertise without travelling to Beijing.

Private-Level IMC Within a Public Hospital

The International Medical Centre operates with dedicated staff, a separate patient flow, and a service standard closer to a private hospital. International patients receive bilingual case coordination, dedicated consultation scheduling, and a designated liaison throughout their stay — at public hospital treatment pricing. China Care coordinates directly with the IMC, pre-clearing your case before you travel.

Clinical Departments

Specialties Available to International Patients

The departments most commonly accessed by international patients coordinated through China Care.

Primary Focus
Dermatology & Skin Oncology
National clinical centre designation. Full spectrum from autoimmune skin diseases (psoriasis, lupus) to melanoma, cutaneous lymphoma, and rare skin cancers. Advanced phototherapy, biologics, and surgical excision all available.
MelanomaCutaneous LymphomaPsoriasisSkin Cancer
Primary Focus
Precision Oncology & CAR-T
NGS genomic profiling integrated into oncology intake. CAR-T cell therapy access via the Peking University clinical trial network for eligible haematological malignancies. Solid tumour oncology with precision medicine protocols.
CAR-T NetworkNGS ProfilingHaematologySolid Tumours
Also Available
Male Health & Urology
Comprehensive urology covering prostate cancer, bladder cancer, kidney disease, and male reproductive health. Minimally invasive laparoscopic procedures and robotic-assisted surgery available for appropriate cases.
Prostate CancerBladder CancerRobotic Surgery
Also Available
Cardiology
Interventional cardiology, echocardiography, and cardiac imaging. Coronary artery disease management and electrophysiology. Collaborative management for oncology patients with cardiac complications.
Coronary InterventionElectrophysiology
Also Available
Neurology & Neurosurgery
Cerebrovascular disease, brain tumours, and spinal conditions. Neurosurgery with microsurgical and minimally invasive techniques. Stroke intervention and neurological rehabilitation programmes.
Brain TumourStrokeSpine
Access via China Care
Not sure which department fits your case?
Submit your records to China Care. We identify the right specialist team at PKU Shenzhen, conduct a proxy consultation on your behalf, and confirm suitability before you travel.
Submit Your Case
Step-by-Step

How to Access Treatment at Peking University Shenzhen Hospital

China Care coordinates the full intake process for international patients — from initial record review through to on-the-ground support during your stay in Shenzhen.

Step 1
Submit Your Records to China Care

Send your medical records, pathology reports, and imaging to China Care. For dermatology or skin oncology cases, include photos and any prior biopsy results. For oncology cases, include complete treatment history and current blood panel. We review your records and prepare a bilingual case summary within 1–2 working days.

records review · 1–2 days
Step 2
China Care Conducts a Proxy Consultation on Your Behalf

China Care attends PKU Shenzhen Hospital in person and consults directly with the relevant specialist — on your behalf, before you travel. The doctor reviews your case summary, indicates whether treatment is suitable, and gives an initial direction. China Care reports the outcome back to you with voice call interpretation in real time during the consultation.

This service is charged at a fixed fee, which covers hospital registration, the in-person proxy consultation, and real-time voice interpretation. Already in China? Skip this step — China Care can arrange direct escort and interpretation for your own visit instead.

proxy consultation · fixed fee · results same day
Step 3
Travel to Shenzhen for Your In-Person Consultation

Armed with the specialist's initial direction, you travel to Shenzhen for your own in-person consultation at the IMC. The specialist reviews your case in full, confirms the treatment plan, and provides a formal cost estimate — this cannot be completed remotely at a public hospital. For oncology cases, NGS genomic profiling is typically initiated at this appointment. China Care's bilingual coordinator accompanies you throughout.

in-person consultation · treatment plan & cost estimate issued
Step 4
Admission & Treatment

Once you agree to proceed, admission is arranged through the IMC. China Care's coordinator remains on hand during your stay — accompanying you to ward rounds, follow-up appointments, and administrative processes. Ward nursing staff and hospital administration operate primarily in Mandarin, so on-site escort is strongly recommended for non-Chinese speakers.

All treatment fees are paid directly to the hospital in Chinese yuan (RMB). PKU Shenzhen Hospital does not accept international credit cards for inpatient treatment. A deposit is required at admission; the balance is settled before discharge. China Care does not collect or handle medical payments.

IMC admission · RMB payment direct to hospital
Step 5
Discharge and Follow-Up

Complete bilingual discharge documentation is issued on the day of discharge. For oncology patients requiring follow-up genomic testing or treatment monitoring, China Care can coordinate remote check-ins with the specialist team depending on the individual physician's availability. Post-discharge coordination with your home physician is also available on request.

bilingual documentation · post-discharge support
Proxy consultation (fixed fee) Bilingual case coordination NGS genomic profiling support CAR-T trial network access In-person escort & interpretation Medical visa support RMB payment direct to hospital Bilingual discharge documents
Before You Travel

What international patients need to know

Payment
RMB only
All fees paid directly to hospital in Chinese yuan. No international credit cards. Deposit required at admission.
Advance booking
1–2 weeks minimum
Walk-in not available for international patients. All appointments coordinated through China Care before you travel.
Location
Futian District
Central Shenzhen. ~25 min from Shenzhen Bay Port (Hong Kong crossing) and ~20 min from Futian Checkpoint.
Language
English (IMC) + escort
IMC attending physicians speak functional English. Ward staff operate in Mandarin. China Care arranges bilingual escort for all consultations.
From Hong Kong
~45–60 min door-to-door
Via Shenzhen Bay Port or Futian Checkpoint. MTR West Rail and direct bus connections available from central Hong Kong.
Hospital type
Public · Grade 3A
Government-funded academic hospital. Treatment costs quoted directly by the hospital — zero markup from China Care.
Common Questions

What patients ask about Peking University Shenzhen Hospital

Is this hospital genuinely affiliated with Peking University in Beijing?
Yes. Peking University Shenzhen Hospital is a direct branch of the Peking University Health Science Centre system — not a licensing arrangement or branding affiliation. Clinical protocols, academic appointments, and research pipelines feed directly from the Beijing campus. Senior faculty hold joint appointments across both institutions. For patients who want Peking University-standard oncology expertise without travelling to Beijing, this Shenzhen campus offers genuine access to the same clinical network.
What makes this hospital the right choice for skin cancer rather than another Shenzhen hospital?
The dermatology department holds national clinical centre designation — one of only a small number of hospitals in China to receive this designation for dermatology specifically. The volume and complexity of cases seen here significantly exceeds most other hospitals in Guangdong Province. For conditions such as melanoma, cutaneous lymphoma, rare genetic skin disorders, or complex autoimmune dermatology, the case volume and specialist depth at PKU Shenzhen is unmatched within the Shenzhen metro area.
Can international patients access CAR-T trials here without going to Beijing?
Access depends on the specific trial and the patient's clinical profile. The PKU network does run CAR-T protocols from this Shenzhen campus, but trial eligibility is determined by the clinical team after reviewing the patient's full history. China Care submits your records in advance, conducts a proxy consultation with the oncology or haematology team, and confirms whether active trial slots are available and whether you qualify — before you commit to travelling from abroad. See our overview of CAR-T cell therapy in China for broader context on eligibility.
How does the IMC differ from the main outpatient department?
The International Medical Centre operates as a separate patient pathway within the hospital. It has its own reception, dedicated appointment scheduling separate from general queues, physicians experienced with international patients, and a service standard closer to private healthcare. The same senior specialists who work in the main clinical departments also see patients through the IMC. For international patients, this means access to the same clinical expertise with significantly better coordination and lower language barriers than navigating the main outpatient department independently.
What is NGS profiling and does this hospital offer it for solid tumour patients?
Next-generation sequencing (NGS) is a comprehensive genomic analysis of tumour tissue that identifies specific mutations, gene fusions, and biomarkers. The results determine which targeted therapies or immunotherapy agents are most likely to be effective for a given patient's tumour profile. Peking University Shenzhen Hospital integrates NGS profiling into its oncology intake pathway, typically initiating it at the first in-person consultation. For patients who have already undergone NGS elsewhere, the results can be incorporated into the specialist's assessment.
How do I pay for treatment and does China Care handle the money?
All treatment fees are paid directly to PKU Shenzhen Hospital in Chinese yuan (RMB). As a public hospital, it does not accept international credit cards for inpatient treatment. A deposit is required at admission; the balance is settled before discharge. China Care does not collect or handle any medical payments on your behalf — your coordination fee is paid separately to China Care in advance. Treatment costs are quoted directly by the hospital and are not marked up by China Care.
Get Started

Ready to enquire about treatment at PKU Shenzhen Hospital?

Submit your records to China Care. We conduct a proxy consultation on your behalf and report back before you commit to travelling.

China Care coordinates your case with PKU Shenzhen Hospital's International Medical Centre. Treatment costs are quoted directly by the hospital. We never add to or mark up the hospital's quoted treatment cost.